9:34 AM ET 2/26/15 | Morningstar
RELATED QUOTES
10:53 AM ET 2/26/15
Symbol Last % Chg
GRFS.ZY
34.12 0.71%
GRFS
34.14 0.78%
Real time quote.
Grifols reported strong results for 2014, with 22% top-line growth (24% at constant currencies) and a 32% adjusted EBITDA margin. This was slightly below our forecast on the top line, but profitability was stronger than we expected, putting bottom-line performance closer to our forecast. We're maintaining our EUR 34 per share ($39 per ADR) fair value estimate, and we remain confident in Grifols' narrow moat, which rests in its significant cost advantages in the global plasma market. While performance was boosted by the Novartis diagnostics acquisition in January, about 60% of Grifols' revenue is derived from North America, likely giving the firm a strong currency tailwind in 2015 and driving continued double-digit growth this year.
Grifols' plasma sales were weaker in 2014, which we believe is due to ex U.S. Factor VIII pressure and a more competitive U.S. hospital sales environment. The Bioscience division (now 75% of revenue) grew 2.6% in 2014 (4% at constant currencies). Performance has improved each quarter this year, but the 4.8% constant currency growth in the fourth quarter was well below the 8% growth in 2013. We think this is largely due to double-digit declines in sales of the firm's Factor VIII products in a very competitive environment, as recombinant products are increasingly used in emerging markets. However, Grifols noted that the U.S. plasma market was quite competitive in 2014 and that it did increase marketing and negotiate contracts (probably implying some pricing pressure, even in this higher-priced market). We think these comments apply to the immunoglobulin market, confirming recent comments from CSL, which pointed to pricing pressure for its fighting brand Carimune in price-sensitive hospital channels. However, we continue to view the top three global plasma firms as holding significant cost advantages over smaller players, and we think pricing power remains strong for premium brands, which are increasingly used chronically and at home.
Recent GRFS News
- Schwab and Snowflake Retreat in Premarket, WeRide Postpones IPO, Halliburton Cyberattack, McDonald’s Instagram Hack • IH Market News • 08/22/2024 09:37:42 AM
- GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2024 06:00:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2024 03:12:47 PM
- Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News • IH Market News • 07/03/2024 10:59:39 AM
- Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years • GlobeNewswire Inc. • 07/01/2024 10:00:44 AM
- Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group • GlobeNewswire Inc. • 06/18/2024 11:30:08 AM
- Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies • GlobeNewswire Inc. • 06/17/2024 08:20:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/14/2024 09:00:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 02:51:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 08:46:16 PM
- Grifols 2023 Annual Report on Form 20-F filed with the SEC • PR Newswire (US) • 04/19/2024 08:42:00 PM
- Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. • GlobeNewswire Inc. • 04/18/2024 01:30:00 PM
- Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News • IH Market News • 04/15/2024 11:06:48 AM
- Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening • GlobeNewswire Inc. • 04/04/2024 08:00:00 AM
- FedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest News • IH Market News • 03/22/2024 01:07:53 PM
- CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News • IH Market News • 03/08/2024 11:19:59 AM
- Grifols announces positive topline phase 3 fibrinogen clinical trial results • GlobeNewswire Inc. • 02/14/2024 08:16:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 10:14:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:05:11 AM
- Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More • IH Market News • 01/12/2024 11:10:50 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 06:08:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 01:59:48 PM
- Wall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and More • IH Market News • 01/10/2024 11:21:31 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM